BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-706 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-706\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05599984-11131@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:ABBV-706: Phase 1 readout est. (NCT05599984)
DESCRIPTION:ABBV-706\, phase 1.\nStudy: Study to Evaluate Adverse Events\, 
 Change in Disease Activity\, and How ABBV-706 Moves Through the Body When 
 Intravenously (IV) Infused Alone or in Combination With IV Infused Budigal
 imab\, Cisplatin\, or Carboplatin in Adult Participants With Advanced Soli
 d Tumors\nEstimated primary completion: November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/abbv-706#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05599984
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-11131@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07155174)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate the Optimal Dose\, Adverse Events and Change in Disease Activity
  of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard 
 of Care as First-Line Treatment in Adult Participants With Previously Untr
 eated Extensive Stage Small Cell Lung Cancer\nEstimated primary completion
 : April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-70
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 155174
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365241-11131@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:ABBV-706: Phase 3 readout est. (NCT07365241)
DESCRIPTION:ABBV-706\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate Adverse Events and Change in Disease Activity of Intravenous ABB
 V-706 Versus Standard of Care in Adult Participants With Relapsed/Refracto
 ry Small Cell Lung Cancer\nEstimated primary completion: September 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/abbv-706#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07365241
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-11131@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07895056)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Assess Adverse Events and Change in Disease Activity of Intravenous (IV) 
 ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Particip
 ants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comple
 tion: August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 bv-706#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07895056
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895043-11131@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07895043)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Assess Adverse Events and Change in Disease Activity of Intravenous (IV) 
 ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Partic
 ipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comp
 letion: December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abbv-706#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07895043
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
